Welcome to see more details about Mazdutide in Phcoker!!
About GLORY-1 (NCT05607680), this Phase 3 clinical trial is evaluating the efficacy and safety of mazdutide in Chinese adults with overweight or obesity. The trial is multi-center, randomized, double-blind, and placebo-controlled, ensuring the highest standards of research. During the 48-week double-blind treatment period, 610 participants were randomized to receive mazdutide 4 mg, 6 mg, or placebo. We are excited to see the results of this groundbreaking study!
The GLORY-1 study was a resounding success! Both mazdutide 4 mg and 6 mg outperformed the placebo in two key areas: the percentage change in body weight from baseline to week 32 and the proportion of participants with a weight loss of ≥5% at week 32. And the best part? The weight-loss efficacy continued to improve from week 32 to week 48!
Furthermore, the study achieved all key secondary endpoints with flying colors! This includes the proportion of participants who experienced significant weight loss of 10% or 15%, as well as improvements in waist circumference, systolic blood pressure, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), total cholesterol, serum uric acid, and alanine aminotransferase (ALT). It's worth noting that mazdutide outperformed the placebo in all of these weight-loss and cardiometabolic endpoints.
During the double-blind treatment period, the safety profile of mazdutide was similar to that observed in previous clinical studies, and no new safety signals were detected. Additionally, its friendly safety profile and lack of new safety signals make it a promising candidate for future treatments. We are confident in the potential of Mazdutide and its ability to positively impact patients' lives.
Excitingly, Mazdutide has become the first GLP-1R/GCGR dual agonist to succeed in Phase 3 trials. As the first registration trial for weight management using mazdutide, the results of GLORY-1 not only confirm the efficacy and safety of mazdutide in a large population but also provide high-quality clinical evidence of long-term pharmacotherapy for weight management, specifically for the Chinese population with overweight or obesity.